Overview

Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis

Status:
NOT_YET_RECRUITING

Trial end date:
2026-11-15

Target enrollment:

Participant gender:

Summary

A Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of Nebulised RESP30TB in Adults with Newly Diagnosed, Rifampicin Susceptible Pulmonary Tuberculosis

Phase:

PHASE2

Details

Lead Sponsor:

Thirty Respiratory Limited

Treatments:

Isoniazid
Pyrazinamide
Rifampin